-
The project of taxol derivative, a class I and type II new antidiabetic drug of Haixi United Pharmaceutical Co., Ltd. was officially launched in Mingxi
Time of Update: 2020-04-03
Fujian Haixi United Pharmaceutical Co., Ltd and China University of Pharmaceutical Sciences jointly implemented a class I new drug taxol derivative (type II new anti diabetes drug) project, which was
-
Shuangcheng pharmaceutical focuses on clinical re declaration after withdrawal of etibatide for injection
Time of Update: 2020-04-03
Hainan Shuangcheng Pharmaceutical Co., Ltd focuses on the research of etibatide, which has attracted market attention since the withdrawal of registration application last year The company said in a p
-
Zuelacetan, an antiepileptic drug of Jingxin pharmaceutical, has obtained new drug certificate and registration approval
Time of Update: 2020-04-03
Zhejiang Jingxin pharmaceutical announced that the company and its wholly-owned subsidiary Shangyu Jingxin Pharmaceutical Co., Ltd received the new drug certificate (Certificate No.: gdzzh20140034) ap
-
The first imitation of the application for production of six kinds of generic drug of HISCO
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on June 18, six generic drugs of HISCO, fondagangui sodium injection, were applied for production and joined in the first simu
-
Xiamen Tebao a new drug pegylated interferon α - 2b injection officially declared for production
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA), Tonghua Dongbao joint stock company Xiamen Tebao Bioengineering Co., Ltd has officially applied for the production of polyeth
-
Clinical approval of recombinant human anti TNF α monoclonal antibody for injection
Time of Update: 2020-04-03
Jiankangyuan and Lizhu group's joint-venture subsidiary announced today (March 7) that Zhuhai Lizhu monoclonal antibody Biotechnology Co., Ltd (hereinafter referred to as monoclonal antibody company)
-
Haizheng Pharmaceutical Co., Ltd. applied for clinical application of class 3.1 chemical drug API for sirolimus and was accepted
Time of Update: 2020-04-03
Recently, according to the website of the State Food and Drug Administration (CFDA), the 3.1 chemical raw material drug tirocimose and preparation injection tirocimose applied for clinical application
-
Xikang cooperates with afinita biotech to develop new anti-cancer monoclonal antibody drugs
Time of Update: 2020-04-03
Xikang (Cayman) Holding Co., Ltd (Emerging Stock Code: 6540) announced that its subsidiary Xikang biotechnology signed a commissioned development and manufacturing contract with afinita biotech of the
-
HongRi pharmaceutical company's first imitative drug for the treatment of venous thromboembolism
Time of Update: 2020-04-03
PTS injection, a new anticancer drug of HongRi pharmaceutical, is still in the stage of production approval and is progressing smoothly We expect that it will be approved and marketed in 2014 The sulf
-
Ceftibuten tablet, a new drug of Lu Kang medicine and antibiotic, is expected to be approved for production as the first imitation this year
Time of Update: 2020-04-03
The 3 kinds of chemical drug APIs and 5 kinds of preparations applied for production by Lu Kang pharmaceutical have entered the stage of waiting for on-site inspection The product is expected to be ap
-
Apg-115, an original and new target precise antitumor drug of AXA pharmaceutical, was approved to enter the US clinical practice
Time of Update: 2020-04-03
June 2, 2016 - on June 1, according to the information from FDA, apg-115, a precision anti-tumor drug with global intellectual property rights and acting on the new target MDM2-p53 independently desig
-
A new anti hepatitis drug of Guizhou bailing, tefentai, will be put into clinical trial soon
Time of Update: 2020-04-03
Recently, the latest status of Guizhou bailing's heavyweight drug, tefentai (original Y101), was changed to "approved - to be certified" This means that the company's class 1.1 innovative drug, tefent
-
Haizheng pharmaceutical's class 3.1 new drug gefitinib API has been accepted
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA), the class 3.1 new drug gefitinib API declared by Haizheng pharmaceutical was accepted At present, only the original research
-
Application for registration of new lung cancer drug toluenesulfonamide production of HongRi Pharmaceutical Co., Ltd. accepted
Time of Update: 2020-04-03
In the afternoon of May 19, HongRi pharmaceutical announced that the application for production registration of p-toluenesulfonamide (hereinafter referred to as "PTS") jointly declared by the company
-
Transforming medicine to develop personalized medicine
Time of Update: 2020-04-03
"Under the trend of personalized medical treatment, the new drugs in the future will no longer be a" blockbuster "with more than one billion dollars, and personalized research and development for the
-
Jiahe biology cooperates with American sharp company to develop innovative biological medicine ryi-008 for tumor and autoimmunity
Time of Update: 2020-04-03
Ryi-008 is an innovative monoclonal antibody against IL-6, which has unique pharmacological properties and is expected to create a new treatment for related diseases This is an important milestone for
-
Review of drugs accepted by CDE in April 2014 (2)
Time of Update: 2020-04-03
In April 2014, CDE accepted 63 clinical applications for new drugs of 2-5 categories of chemicals, including 9 anti-tumor drugs, 7 respiratory drugs, 6 digestive system drugs, 6 blood and hematopoieti
-
Chinese and American researchers found that the combination of diphosphonic acid and rapamycin can treat drug-resistant lung cancer
Time of Update: 2020-04-03
Chinese and American researchers said Tuesday they have found a promising treatment for drug-resistant lung cancer The results showed that the survival time of mice with cancer could be doubled by usi
-
Hanyu pharmaceutical's new drug enkephalin and injection enter the site for inspection
Time of Update: 2020-04-03
According to the website of the State Food and Drug Administration (CFDA) on April 11, Hanyu pharmaceutical's heavyweight new drug, enkephalin and enkephalin injection, has entered the site for inspec
-
Yikoning, the world's first hepatitis E vaccine developed in China, will go on the market in October
Time of Update: 2020-04-03
Behind the development of the world's first hepatitis E vaccine China is a high prevalence area of hepatitis E, but the public's understanding of hepatitis E is relatively low, and the harm of hepatit
